Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects
A Single-center, Open-label, Drug-drug Interaction Study of XZP-3287 Tablets in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Zhimin Zhou
- Phone Number: 0086-13647211506
- Email: zhouzhimin@xuanzhubio.com
Study Locations
-
-
Anhui
-
Bengbu, Anhui, China
- Recruiting
- the First Affiliated Hospital of Bengbu Medical College
-
Contact:
- Huan Zhou
- Phone Number: 0086-0522-3086943
- Email: zhouhuanbest@vip.163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female subjects aged 18 to 65 years (including 18 and 65);
- Male body weight ≥50kg, female body weight ≥45kg, body mass index between 18 to 28 kg/m2 (inclusive).
- No medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system.
- Subjects shall ake effective contraceptive measures voluntarily within 3 months from the date of signing the informed consent form (for women, 2 weeks before trial screening) to the date of the last medication.
- Willing and able to comply with all scheduled visits, study procedures, and provides written informed consent
Exclusion Criteria:
- Allergic constitution and those with known allergy to XZP-3287 or similar drugs and excipients
- Abnormal clinical tests and clinical significance judged by the investigator
- Frequent use of sedatives, sleeping pills or other addictive drugs within 6 months before enrollment
- History of drug use, or drug abuse screening positive
- Those who had smoked more than 5 cigarettes per day on average in the 3 months before the screening period or habitually used nicotine-containing products and were unable to quit during the test period
- Heavy drinking or regular drinking in the six months preceding the screening period
- Use of any prescription drug or Chinese herbal medicine within 4 weeks prior to enrollment, or use of any over-the-counter drug, any vitamin product, health care drug within 14 days prior to enrollment;
- Treatment with an investigational drug within 3 months
- Participated in blood donation with blood donation volume ≥400 mL or received blood transfusion within 3 months before screening.
- Had a severe infection, trauma or major surgery within 4 weeks of screening
- Gastrointestinal disorders causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndromes
- Pregnant or lactating women, or subjects cannot take strict contraceptive measures as required.
- Hepatitis B surface antigen or E antigen, hepatitis C antibody, HIV antibody and syphilis antibody, any of which are positive.
- Allergic to any food ingredients or has special requirements on diet, cannot follow the unified diet
- habitual consumption of food or beverage containing methylxanthine, such as tea, coffee, cola, chocolate and so on during the study period
- habitual consumption of grapefruit juice during the study period
- have difficulty in blood collection or cannot tolerate vein puncture for blood collection
- As determined by the investigator, the subject has other factors that are not suitable for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: XZP-3287 combined with clarithromycin
|
Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21
|
|
Experimental: XZP-3287 combined with rifampicin
|
Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary PK Endpoints
Time Frame: day 1~day 20/day22
|
Cmax
|
day 1~day 20/day22
|
|
Primary PK Endpoints
Time Frame: day 1~day 20/day22
|
AUC0-∞
|
day 1~day 20/day22
|
|
Primary PK Endpoints
Time Frame: day 1~day 20/day22
|
AUC0-t
|
day 1~day 20/day22
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Secondary PK measures
Time Frame: day 1~day 20/day22
|
Tmax
|
day 1~day 20/day22
|
|
Secondary PK measures
Time Frame: day 1~day 20/day22
|
T1/2
|
day 1~day 20/day22
|
|
Secondary PK measures
Time Frame: day 1~day 20/day22
|
CL/F
|
day 1~day 20/day22
|
|
Secondary PK measures
Time Frame: day 1~day 20/day22
|
Vz/F
|
day 1~day 20/day22
|
|
SAFETY/TOLERABILITY
Time Frame: Up to 10 days after last dose
|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE 5.0
|
Up to 10 days after last dose
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Leprostatic Agents
- Protein Synthesis Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Rifampin
- Clarithromycin
Other Study ID Numbers
Other Study ID Numbers
- XZP-3287-1003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.